Matthew Herper says U.S. venture capital firms are embedding inside Chinese biotech labs and courting scientists before they publish, rather than waiting for assets to surface.
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface
they’re moving upstream, embedding themselves inside labs
courting scientists before they publish their research
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare